Francesca Lessi
YOU?
Author Swipe
View article: P05.13.A DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING
P05.13.A DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING Open
INTRODUCTION Recent breakthroughs in single-cell analysis reveal distinct metabolic cellular states of glioblastoma (GBM) and allow the detection of GBMs which are dependent on oxidative phosphorylation (OXPHOS). The aims of the study was …
View article: P03.14.A BEYOND CONVENTIONAL PATHOLOGY: ADDING AN EXTRA LAYER OF INSIGHT WITH NADH-FLIM TO REVEAL HIDDEN METABOLIC PROFILES IN GLIOBLASTOMA
P03.14.A BEYOND CONVENTIONAL PATHOLOGY: ADDING AN EXTRA LAYER OF INSIGHT WITH NADH-FLIM TO REVEAL HIDDEN METABOLIC PROFILES IN GLIOBLASTOMA Open
BACKGROUND Glioblastoma is one of the most aggressive brain cancers, marked by rapid progression and resistance to treatment. Its cellular heterogeneity and invasive nature make it particularly hard to manage. New tools are needed to bette…
View article: P12.34.A TRACKING INDIVIDUAL AND COLLECTIVE CELLULAR DIFFUSION IN PATIENT-DERIVED PRIMARY GBM CELL LINES: EXPLORING CELL DIFFUSION PROPERTIES AS A POTENTIAL VULNERABILITY IN GLIOBLASTOMA
P12.34.A TRACKING INDIVIDUAL AND COLLECTIVE CELLULAR DIFFUSION IN PATIENT-DERIVED PRIMARY GBM CELL LINES: EXPLORING CELL DIFFUSION PROPERTIES AS A POTENTIAL VULNERABILITY IN GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GBM) is one of the most aggressive and deadly brain tumors, with a median survival of ~14 months. Its poor prognosis is largely due to its ability to infiltrate healthy brain tissue both as single cells and in coll…
View article: CellHit: a web server to predict and analyze cancer patients’ drug responsiveness
CellHit: a web server to predict and analyze cancer patients’ drug responsiveness Open
We present the CellHit web server (https://cellhit.bioinfolab.sns.it/), a web-based platform designed to predict and analyze cancer patients’ responsiveness to drugs using transcriptomic data. By leveraging extensive pharmacogenomics datas…
View article: Corrigendum: Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response early
Corrigendum: Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response early Open
[This corrects the article DOI: 10.3389/fonc.2022.969812.].
View article: Learning and actioning general principles of cancer cell drug sensitivity
Learning and actioning general principles of cancer cell drug sensitivity Open
High-throughput screening of drug sensitivity of cancer cell lines (CCLs) holds the potential to unlock anti-tumor therapies. In this study, we leverage such datasets to predict drug response using cell line transcriptomics, focusing on mo…
View article: Correction: Franceschi et al. Sedoheptulose Kinase SHPK Expression in Glioblastoma: Emerging Role of the Nonoxidative Pentose Phosphate Pathway in Tumor Proliferation. Int. J. Mol. Sci. 2022, 23, 5978
Correction: Franceschi et al. Sedoheptulose Kinase SHPK Expression in Glioblastoma: Emerging Role of the Nonoxidative Pentose Phosphate Pathway in Tumor Proliferation. Int. J. Mol. Sci. 2022, 23, 5978 Open
In the original publication [...]
View article: Exploring Extracellular Vesicle Surface Protein Markers Produced by Glioblastoma Tumors: A Characterization Study Using In Vitro 3D Patient-Derived Cultures
Exploring Extracellular Vesicle Surface Protein Markers Produced by Glioblastoma Tumors: A Characterization Study Using In Vitro 3D Patient-Derived Cultures Open
Background/Objectives: Glioblastoma (GBM) is an aggressive brain cancer with limited treatment options. Extracellular vesicles (EVs) derived from GBM cells contain important biomarkers, such as microRNAs, proteins, and DNA mutations, which…
View article: P10.26.A UTILIZING HIGH-THROUGHPUT SCREENING PLATFORMS FOR PROFILING DRUG SENSITIVITY ACROSS MULTIPLE CANCER CELL LINES TO UNLOCK NEW TARGETED THERAPIES IN GLIOBLASTOMA
P10.26.A UTILIZING HIGH-THROUGHPUT SCREENING PLATFORMS FOR PROFILING DRUG SENSITIVITY ACROSS MULTIPLE CANCER CELL LINES TO UNLOCK NEW TARGETED THERAPIES IN GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GBM) presents a significant challenge in oncology, characterized by its aggressive nature and bleak prognosis. Despite advancements in medical science, such as the introduction of Temozolomide as the standard treat…
View article: P04.01.B DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING
P04.01.B DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING Open
BACKGROUND Recent breakthroughs in single-cell analysis reveal distinct metabolic cellular states, leading to a novel classification of glioblastoma (GBM). An RNA Sequencing methodology optimized for FFPE tumor tissue of GBM allows for the…
View article: P08.02.B BEYOND THE EXPECTED: CIRCULATING TUMOR CELLS IN GLIOBLASTOMA REVEAL HIDDEN HETEROGENEITY AND BECOME POTENTIAL DIAGNOSTIC BIOMARKERS
P08.02.B BEYOND THE EXPECTED: CIRCULATING TUMOR CELLS IN GLIOBLASTOMA REVEAL HIDDEN HETEROGENEITY AND BECOME POTENTIAL DIAGNOSTIC BIOMARKERS Open
BACKGROUND For many years, glioblastoma (GBM) was thought to be restricted to the brain. Nevertheless, a growing body of evidence indicates that, like many other cancers, hematogenic dissemination is a reality. Detection of circulating tum…
View article: P26.14.B VITAMIN D3 ENHANCES TEMOZOLOMIDE EFFICACY IN GLIOBLASTOMA CELLS WHILE PROTECTING NORMAL ASTROCYTES: INVESTIGATING THE EFFECTS OF ADJUNCTIVE THERAPY
P26.14.B VITAMIN D3 ENHANCES TEMOZOLOMIDE EFFICACY IN GLIOBLASTOMA CELLS WHILE PROTECTING NORMAL ASTROCYTES: INVESTIGATING THE EFFECTS OF ADJUNCTIVE THERAPY Open
BACKGROUND Glioblastoma (GB), the most aggressive brain tumor, poses challenges due to resistance to temozolomide (TMZ) and radiotherapy. Regorafenib (REGO) is used as second-line treatment for recurrences. Recent studies suggest potential…
View article: OS07.8.A INNOVATIVE DYNAMIC STRATIFICATION IN GLIOBLASTOMA: ANALYZING TUMOR CELL CHARACTERISTICS AND MOBILITY STRATEGIES THROUGH SINGLE CELL BEHAVIOR LIVE IMAGING (SCBLI)
OS07.8.A INNOVATIVE DYNAMIC STRATIFICATION IN GLIOBLASTOMA: ANALYZING TUMOR CELL CHARACTERISTICS AND MOBILITY STRATEGIES THROUGH SINGLE CELL BEHAVIOR LIVE IMAGING (SCBLI) Open
BACKGROUND Glioblastoma, a highly aggressive brain tumor, presents a daunting prognosis with an average survival of under 15 months due to its invasive nature. Understanding the specific behaviors of individual tumor cells in terms of volu…
View article: P18.15.B DRUG SENSITIVITY OF RECURRENT GBM PATIENT-DERIVED ORGANOIDS CORRELATES WITH PATIENTS’ RESPONSE TO SECOND LINE CHEMOTHERAPY
P18.15.B DRUG SENSITIVITY OF RECURRENT GBM PATIENT-DERIVED ORGANOIDS CORRELATES WITH PATIENTS’ RESPONSE TO SECOND LINE CHEMOTHERAPY Open
OBJECTIVE This study aimed to explore the correlation between the effectiveness of second-line chemotherapy in patients with recurrent glioblastoma (rGBM) who underwent a second surgery and drug treatment tests on patient-derived organoids…
View article: Learning and actioning general principles of cancer cell drug sensitivity
Learning and actioning general principles of cancer cell drug sensitivity Open
High-throughput screening platforms for the profiling of drug sensitivity of hundreds of cancer cell lines (CCLs) have generated large datasets that hold the potential to unlock targeted, anti-tumor therapies. In this study, we leveraged t…
View article: Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling
Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling Open
Glioblastoma, a deadly brain tumor, shows limited response to standard therapies like temozolomide (TMZ). Recent findings from the REGOMA trial underscore a significant survival improvement offered by Regorafenib (REGO) in recurrent gliobl…
View article: Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors Through Longitudinal In Vitro Sampling
Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors Through Longitudinal In Vitro Sampling Open
Glioblastoma, a deadly brain tumor, shows limited response to standard therapies like te-mozolomide (TMZ). Recent findings from the REGOMA trial underscore a significant survival improvement offered by regorafenib (REGO) in recurrent gliob…
View article: NIMG-70. TRACKING CELLULAR SOCIAL BEHAVIOR OF PATIENT-DERIVED PRIMARY CELL LINES TO GATHER NEW INSIGHTS FOR BETTER STRATIFICATION OF GLIOBLASTOMA PATIENTS
NIMG-70. TRACKING CELLULAR SOCIAL BEHAVIOR OF PATIENT-DERIVED PRIMARY CELL LINES TO GATHER NEW INSIGHTS FOR BETTER STRATIFICATION OF GLIOBLASTOMA PATIENTS Open
Glioblastoma is one of the most frequent and aggressive brain tumors. The average life of these patients is on average less than 15 months, due to the proliferation and invasiveness of the tumor cells, which not only constitute the tumor m…
View article: EXTH-83. BIRC3 AS A PREDICTOR OF OUTCOME AND A NEW THERAPEUTIC TARGET IN TMZ RESISTANT GLIOBLASTOMA TUMORS
EXTH-83. BIRC3 AS A PREDICTOR OF OUTCOME AND A NEW THERAPEUTIC TARGET IN TMZ RESISTANT GLIOBLASTOMA TUMORS Open
Glioblastoma (GBM) is an incurable malignant brain tumor, with a highly unfavorable prognosis. Apart from MGMT promoter methylation and TMZ response, molecular biomarkers associated with therapeutic response or survival prognosis are still…
View article: P17.16.B INVESTIGATION OF REGORAFENIB TUMOR SENSITIVITY AND UNDERLYING TREATMENT INDUCED MOLECULAR MECHANISMS IN GLIOBLASTOMA RECURRENT TUMORS
P17.16.B INVESTIGATION OF REGORAFENIB TUMOR SENSITIVITY AND UNDERLYING TREATMENT INDUCED MOLECULAR MECHANISMS IN GLIOBLASTOMA RECURRENT TUMORS Open
BACKGROUND Glioblastoma (GB) is the most aggressive brain malignant tumor with a highly unfavorable prognosis. Maximal surgery resection, temozolomide chemotherapy (TMZ), and radiotherapy (RT), currently remain the best treatment option. R…
View article: P10.10.B BIRC3 AS A PREDICTOR OF OUTCOME AND A NEW THERAPEUTIC TARGET IN TMZ RESISTANT GLIOBLASTOMA TUMORS
P10.10.B BIRC3 AS A PREDICTOR OF OUTCOME AND A NEW THERAPEUTIC TARGET IN TMZ RESISTANT GLIOBLASTOMA TUMORS Open
BACKGROUND Glioblastoma (GB) is the most aggressive malignant tumor of the central nervous system, with a highly unfavorable prognosis with a median survival of 15 months. The standard treatment consists of surgical resection, chemotherapy…
View article: P17.02.B CORRELATIONS BETWEEN CLINICAL BENEFIT TO SECOND LINE REGIMENS AND NADH-FLIM-BASED DRUG RESPONSE ASSESSMENT MODEL ON RECURRENT GBM PATIENT-DERIVED ORGANOIDS
P17.02.B CORRELATIONS BETWEEN CLINICAL BENEFIT TO SECOND LINE REGIMENS AND NADH-FLIM-BASED DRUG RESPONSE ASSESSMENT MODEL ON RECURRENT GBM PATIENT-DERIVED ORGANOIDS Open
OBJECTIVE To investigate the ex-vivo/in-vivo correlation between clinical benefit to second line chemotherapy regimens in patients with recurrent glioblastoma (GBM) who underwent second surgery and NADH-FLIM-based drug response assessment …
View article: P14.04.B CIRCULATING TUMOR CELLS AS A NON-INVASIVE GLIOBLASTOMA DIAGNOSTIC AND PROGNOSTIC TOOL
P14.04.B CIRCULATING TUMOR CELLS AS A NON-INVASIVE GLIOBLASTOMA DIAGNOSTIC AND PROGNOSTIC TOOL Open
BACKGROUND Circulating tumor cells (CTCs) detection in the blood of glioblastoma (GBM) patients can facilitate the assessment of tumoral information without the need for invasive approaches. Our aim is to use GBM CTCs to obtain knowledge a…